Last updated: 5 September 2024 at 11:57am EST

Emil Kakkis Net Worth




The estimated Net Worth of Emil D Kakkis is at least $180 Millón dollars as of 3 September 2024. Emil Kakkis owns over 20,000 units of Ultragenyx Pharmaceutical stock worth over $125,277,075 and over the last 21 years he sold RARE stock worth over $47,791,998. In addition, he makes $6,586,480 as President, Chief Executive Officer y Director at Ultragenyx Pharmaceutical.

Emil Kakkis RARE stock SEC Form 4 insiders trading

Emil has made over 48 trades of the Ultragenyx Pharmaceutical stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of RARE stock worth $1,117,000 on 3 September 2024.

The largest trade he's ever made was selling 75,000 units of Ultragenyx Pharmaceutical stock on 25 November 2008 worth over $1,198,500. On average, Emil trades about 12,532 units every 87 days since 2003. As of 3 September 2024 he still owns at least 2,223,985 units of Ultragenyx Pharmaceutical stock.

You can see the complete history of Emil Kakkis stock trades at the bottom of the page.





Emil Kakkis biography

Dr. Emil D. Kakkis M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. Prior to Ultragenyx, Dr. Kakkis served from September 1998 to February 2009 in various executive capacities, and ultimately as Chief Medical Officer, at BioMarin Pharmaceutical Inc., a biopharmaceutical company. Dr. Kakkis then served as a development consultant to BioMarin from 2009 through 2010. Dr. Kakkis is also Founder of EveryLife Foundation for Rare Diseases, a non-profit organization he started in 2009 to accelerate biotechnology innovation for rare diseases. Dr. Kakkis is board certified in Medical Genetics and was board certified in Pediatrics. He holds a B.A. in Biology from Pomona College and received combined M.D. and Ph.D. degrees from the UCLA School of Medicine’s Medical Scientist Training Program where he received the Bogen prize for his research. Kakkis possesses specific expert knowledge of genetics and rare diseases and operational experience in the life sciences sector that qualify him to serve on our Board.

What is the salary of Emil Kakkis?

As the President, Chief Executive Officer y Director of Ultragenyx Pharmaceutical, the total compensation of Emil Kakkis at Ultragenyx Pharmaceutical is $6,586,480. There are no executives at Ultragenyx Pharmaceutical getting paid more.



How old is Emil Kakkis?

Emil Kakkis is 59, he's been the President, Chief Executive Officer y Director of Ultragenyx Pharmaceutical since . There are 7 older and 16 younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical Inc. is William Aliski, 73, who is the Independent Director.

What's Emil Kakkis's mailing address?

Emil's mailing address filed with the SEC is C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO, CA, 94949.

Insiders trading at Ultragenyx Pharmaceutical

Over the last 11 years, insiders at Ultragenyx Pharmaceutical have traded over $102,813,606 worth of Ultragenyx Pharmaceutical stock and bought 203,500 units worth $4,623,050 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Llc Fmr y Clay B Siegall. On average, Ultragenyx Pharmaceutical executives and independent directors trade stock every 17 days with the average trade being worth of $573,045. The most recent stock trade was executed by Emil D Kakkis on 3 September 2024, trading 20,000 units of RARE stock currently worth $1,117,000.



What does Ultragenyx Pharmaceutical do?

ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d



What does Ultragenyx Pharmaceutical's logo look like?

Ultragenyx Pharmaceutical Inc. logo

Complete history of Emil Kakkis stock trades at Biomarin Pharmaceutical y Ultragenyx Pharmaceutical

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
3 Sep 2024 Emil D Kakkis
Presidente y CEO
Venta 20,000 $55.85 $1,117,000
3 Sep 2024
2,223,985
6 Aug 2024 Emil D Kakkis
Presidente y CEO
Venta 20,000 $50.17 $1,003,400
6 Aug 2024
2,243,985
7 Feb 2024 Emil D Kakkis
Presidente y CEO
Venta 30,000 $45.00 $1,350,000
7 Feb 2024
539,770
29 Dec 2023 Emil D Kakkis
Presidente y CEO
Venta 30,000 $47.87 $1,436,100
29 Dec 2023
569,770
19 Oct 2023 Emil D Kakkis
Presidente y CEO
Uso de opción 47,853 $6.86 $328,272
19 Oct 2023
647,029
30 Dec 2022 Emil D Kakkis
Presidente y CEO
Venta 19,582 $45.57 $892,352
30 Dec 2022
541,108
3 May 2021 Emil D Kakkis
Presidente y CEO
Venta 30,000 $107.80 $3,234,000
3 May 2021
2,259,741
1 Mar 2021 Emil D Kakkis
Presidente y CEO
Venta 30,000 $141.80 $4,254,000
1 Mar 2021
2,289,741
4 Jan 2021 Emil D Kakkis
Presidente y CEO
Venta 30,000 $136.90 $4,107,000
4 Jan 2021
2,329,741
2 Nov 2020 Emil D Kakkis
Presidente y CEO
Venta 30,000 $96.82 $2,904,600
2 Nov 2020
2,359,741
1 Sep 2020 Emil D Kakkis
Presidente y CEO
Venta 30,000 $82.63 $2,478,900
1 Sep 2020
2,389,741
13 Jul 2020 Emil D Kakkis
Presidente y CEO
Venta 40,000 $85.35 $3,414,000
13 Jul 2020
2,419,741
11 Sep 2019 Emil D Kakkis
Presidente y CEO
Comprar 5,000 $43.63 $218,150
11 Sep 2019
472,479
28 Aug 2017 Emil D Kakkis
Presidente y CEO
Comprar 7,500 $52.52 $393,900
28 Aug 2017
2,559,741
15 Nov 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $81.29 $1,625,800
15 Nov 2016
447,147
14 Oct 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $63.02 $1,260,400
14 Oct 2016
467,147
14 Oct 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $63.02 $1,260,400
14 Oct 2016
467,147
15 Aug 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $67.61 $1,352,200
15 Aug 2016
487,147
15 Aug 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $67.61 $1,352,200
15 Aug 2016
487,147
15 Jul 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $50.85 $1,017,000
15 Jul 2016
507,147
15 Jul 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $50.85 $1,017,000
15 Jul 2016
507,147
16 May 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $59.95 $1,199,000
16 May 2016
517,519
15 Apr 2016 Emil D Kakkis
Presidente y CEO
Venta 20,000 $70.33 $1,406,600
15 Apr 2016
537,519
30 Dec 2015 Emil D Kakkis
Presidente y CEO
Venta 20,000 $114.52 $2,290,400
30 Dec 2015
575,640
30 Nov 2015 Emil D Kakkis
Presidente y CEO
Venta 20,000 $98.27 $1,965,400
30 Nov 2015
595,640
30 Oct 2015 Emil D Kakkis
Presidente y CEO
Venta 20,000 $99.57 $1,991,400
30 Oct 2015
615,640
2 Mar 2009 Emil D Kakkis
SVP y Business Operations
Uso de opción 7,897 $6.43 $50,778
2 Mar 2009
47,518
3 Feb 2009 Emil D Kakkis
SVP y Business Operations
Uso de opción 17,000 $6.43 $109,310
3 Feb 2009
56,621
2 Jan 2009 Emil D Kakkis
SVP y Business Operations
Uso de opción 17,000 $6.31 $107,270
2 Jan 2009
56,621
1 Dec 2008 Emil D Kakkis
SVP y Business Operations
Uso de opción 17,000 $6.13 $104,210
1 Dec 2008
56,621
25 Nov 2008 Emil D Kakkis
SVP y Business Operations
Venta 75,000 $15.98 $1,198,500
25 Nov 2008
39,621
31 Oct 2008 Emil D Kakkis
SVP y Business Operations
Uso de opción 33,000 $12.30 $405,900
31 Oct 2008
114,621
1 Oct 2008 Emil D Kakkis
SVP y Business Operations
Uso de opción 18,000 $6.13 $110,340
1 Oct 2008
133,304
2 Sep 2008 Emil D Kakkis
SVP y Business Operations
Venta 18,000 $30.19 $543,420
2 Sep 2008
115,304
1 Aug 2008 Emil D Kakkis
SVP y Business Operations
Venta 18,000 $32.48 $584,640
1 Aug 2008
127,304
7 Jul 2008 Emil D Kakkis
SVP y Business Operations
Venta 18,000 $28.06 $505,080
7 Jul 2008
145,304
2 Jun 2008 Emil D Kakkis
SVP y Business Operations
Venta 18,000 $37.63 $677,340
2 Jun 2008
160,804
30 Apr 2008 Emil D Kakkis
SVP y Business Operations
Uso de opción 18,000 $4.00 $72,000
30 Apr 2008
180,804
29 Apr 2008 Emil D Kakkis
SVP y Business Operations
Uso de opción 75,000 $4.00 $300,000
29 Apr 2008
161,164
1 Apr 2008 Emil D Kakkis
SVP y Business Operations
Venta 9,857 $35.90 $353,866
1 Apr 2008
86,164
1 Apr 2008 Emil D Kakkis
SVP y Business Operations
Uso de opción 18,000 $4.00 $72,000
1 Apr 2008
104,164
6 Mar 2008 Emil D Kakkis
SVP y Business Operations
Uso de opción 18,000 $4.00 $72,000
6 Mar 2008
104,164
31 Oct 2007 Emil D Kakkis
SVP y Business Operations
Comprar 2,038 $6.92 $14,103
31 Oct 2007
96,164
30 Apr 2007 Emil D Kakkis
SVP y Business Operations
Comprar 2,982 $5.19 $15,477
30 Apr 2007
94,126
4 Jan 2007 Emil D Kakkis
SVP y Business Operations
Uso de opción 50,000 $4.00 $200,000
4 Jan 2007
88,144
31 Oct 2006 Emil D Kakkis
SVP y Business Operations
Comprar 4,368 $3.43 $14,982
31 Oct 2006
38,144
6 May 2004 Emil D Kakkis
SVP y Business Operations
Comprar 15,000 $6.49 $97,350
6 May 2004
26,110
29 Dec 2003 Emil D Kakkis
SVP y Business Operations
Uso de opción 10,187 $7.00 $71,309
29 Dec 2003
21,297


Ultragenyx Pharmaceutical executives and stock owners

Ultragenyx Pharmaceutical executives and other stock owners filed with the SEC include: